Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05296421 · ClinicalTrials.gov registry record · NA
Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
A NA study of Pancreatic Ductal Adenocarcinoma, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT05296421 is a NA study of Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 16 participants, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05296421, a NA study of Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical trial investigates the nutrients pancreatic cancers depend on in which to survive and the processes these tumors use (metabolism) to obtain these nutrients. Giving U-13C-glucose during surgery may allow doctors to trace the metabolic activity of pancreatic cancer in research experiments done in the laboratory. These experiments may help researchers understand how cancer cells manage their nutrients when compared to normal pancreatic cells.
Conditions Studied
Interventions
- PROCEDURE Biopsy
- PROCEDURE Therapeutic Conventional Surgery
- OTHER Uniformly-labeled [13C]glucose
Study Locations (2)
New Jersey
- Cooperman Barnabas Medical Center (Saint Barnabas Medical Center) - Livingston
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2026-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05296421
The ClinicalTrials.gov registry entry for NCT05296421 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (97% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Biopsy is the first listed.
NCT05296421 reports 2 study locations spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05296421 about?
NCT05296421 is a clinical study titled "Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer". This clinical trial investigates the nutrients pancreatic cancers depend on in which to survive and the processes these tumors use (metabolism) to obtain these nutrients. Giving U-13C-glucose during surgery may allow doctors to trace the metabolic activity of pancreatic cancer in research experiment...
What is the current status of trial NCT05296421?
This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2022-03-14. Estimated completion is 2026-07-01.
What conditions does trial NCT05296421 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT05296421?
The interventions under investigation include: Biopsy (PROCEDURE), Therapeutic Conventional Surgery (PROCEDURE), Uniformly-labeled [13C]glucose (OTHER).
Who is sponsoring clinical trial NCT05296421?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05296421 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
RECRUITING · NA
-
Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center
ACTIVE NOT RECRUITING · NA
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
RECRUITING
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.